DelMar Pharmaceuticals, Inc. (DMPI) Starts Presentation at Biotech Showcase Conference

DelMar Pharmaceuticals, Inc. (OTC: DMPI) is a clinical and commercial stage drug development company with a focus on the treatment of cancer. The company is in the midst of conducting clinical trials in the U.S. with its product candidate, VAL-083, which is designed to serve as a potential new treatment for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. For more information, visit the company’s website at www.delmarpharma.com.